Susan Parry is Associate Professor of Gastroenterology specialising in familial gastrointestinal cancers. She is the Clinical Director of the New Zealand Gastrointestinal Cancer Service, and Clinical Director of the Ministry of Health Bowel Cancer Programme. She leads the New Zealand Familial GI Cancer Service.

Maurizio Genuardi is Professor of Medical Genetics and Director of the Institute of Medical Genomics at the Catholic University, and Director of Medical Genetics Services at Policlinico Agostino Gemelli University Hospital in Rome. He has chaired the InSiGHT Variant Interpretation Committee since 2007, and coordinated the Cancer Genetics Working Group of the Italian Society of Human Genetics (SIGU) 2012-15 and is the President Elect of SIGU.

Tom Weber is Professor of Surgery at the State University of New York at Downstate and Chief of Surgery at the Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn Campus. He is a recent past President of the Collaborative Group of the Americas for the study of Hereditary Colorectal Cancer and a member of InSiGHT and has recently joined the Advisory Board of the Human Variome Project.

Finlay Macrae is Professor in the Department of Medicine, University of Melbourne, Australia and Head of Colorectal Medicine and Genetics at The Royal Melbourne Hospital. He was a founding member of the antecedent Leeds Castle Polyposis Group, and instigated creation of the InSiGHT MMR database, its Variant Interpretation Committee, and the association with the Human Variome Project.

James Church holds the Victor W Fazio Chair in Colorectal Surgery at the Cleveland Clinic and has been Director of the David G Jagelman Inherited Colorectal Cancer Registry at the Cleveland Clinic since 1989, and Director of the Sanford R Weiss Center for Hereditary Colorectal Neoplasia since its inception in 2008. He was Chair of the LCPG and ICG-HNPCC in 2002-03 and founded the Collaborative Group of the Americas for Inherited Colorectal Cancer in 1996.

Gabriel Capella is Director of the Hereditary Cancer Program at the Catalan Institute of Oncology. He trained as a general and digestive surgeon in Barcelona, and is also accredited in Human Genetics by the Spanish Society of Human Genetics. His research focuses in the study of the genetic basis of gastrointestinal cancer with a particular interest in hereditary colorectal cancer.

Ian Frayling is Consultant in Genetic Pathology in Cardiff, Wales. His work now concentrates on mutation interpretation and systematic testing of incident cancers to identify hereditary cases. He is also an assessor for the UK National External Quality Assessment Scheme in Immunohistochemistry. He is a founder member of InSiGHT, InSiGHT’s Variant Interpretation Committee, and the Mallorca Group.

Nicoline Hoogerbrugge is Professor in Hereditary Cancer at Radboud University Medical Center, Nijmegen. She has been directly involved in identification of several genes involved in hereditary colorectal cancer, including EPCAM, BUB1, BUB3,FOCAD and recently NTHL1. She also works on dendritic cell vaccinations for cancer prevention in healthy carries of a Lynch syndrome mutation.

Andrew Latchford is Consultant Gastroenterologist at St Mark's Hospital and Honorary Senior Lecturer at Imperial College, London. He is Assistant Director of the St Mark's Hospital Polyposis Registry and currently supervises research on upper GI tract disease in polyposis syndromes, pouch polyps in FAP, serrated polyposis syndrome and identification/management outcomes in Lynch syndrome. He was an expert advisor to NICE in the development of guidelines for universal tumour MMR testing.

Patrick Lynch is Professor of Medicine, Department of Gastroenterology, Hepatology, Nutrition, University of Texas MD Anderson Cancer Centre. He has been a member of InSiGHT since its inception and was Co-chair 2009-11. He was a member of the predecessor organizations, the LCPG and ICG-HNPCC. His current interest is the development of a web-based platform for communication of risk information within mutation-positive families. He will be running in the 2016 New York Marathon to raise funds for InSiGHT.

Allan Spigelman is Professor of Surgery at the University of New South Wales, and Director of St Vincent's Hereditary Cancer Clinic. He described the most widely used classification for upper gastrointestinal polyposis in FAP patients while a research fellow at St Mark’s Hospital. He has gone on to establish cancer genetic clinics across his state in Australia, and remains active in the cancer genetic research area. He was Chair of InSiGHT council and hosted the biennial meeting of InSiGHT in Cairns in 2013.